Cargando…

Multiple sclerosis disease-modifying drug use by immigrants: a real-world study

Little is known about disease-modifying drug (DMD) initiation by immigrants with multiple sclerosis (MS) in countries with universal health coverage. We assessed the association between immigration status and DMD use within 5-years after the first MS-related healthcare encounter. Using health admini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graf, Jonas, Ng, Huah Shin, Zhu, Feng, Zhao, Yinshan, Wijnands, José M. A., Evans, Charity, Fisk, John D., Marrie, Ruth Ann, Tremlett, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692166/ https://www.ncbi.nlm.nih.gov/pubmed/38040796 http://dx.doi.org/10.1038/s41598-023-46313-7

Ejemplares similares

Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits
por: Graf, Jonas, et al.
Publicado: (2022)

Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
por: Ng, Huah Shin, et al.
Publicado: (2022)

Disease-modifying drugs for multiple sclerosis and subsequent health service use
por: Ng, Huah Shin, et al.
Publicado: (2021)

Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population
por: Ng, Huah Shin, et al.
Publicado: (2022)

Sex and age differences in the Multiple Sclerosis prodrome
por: Yusuf, Fardowsa L. A., et al.
Publicado: (2022)

Polypharmacy and multiple sclerosis: A population-based study
por: Chertcoff, Anibal, et al.
Publicado: (2022)

Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study
por: McKay, Kyla A, et al.
Publicado: (2016)

Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study
por: Evans, Charity, et al.
Publicado: (2021)

Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study
por: Zhang, Tingting, et al.
Publicado: (2017)

Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis
por: Zhang, Tingting, et al.
Publicado: (2016)

Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children
por: Razaz, Neda, et al.
Publicado: (2016)

Etiology, effects and management of comorbidities in multiple sclerosis: recent advances
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort
por: Melesse, Dessalegn Y, et al.
Publicado: (2017)

Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance
por: Marrie, Ruth Ann, et al.
Publicado: (2013)

Children and adolescents adjustment to parental multiple sclerosis: a systematic review
por: Razaz, Neda, et al.
Publicado: (2014)

Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study
por: McKay, Kyla A., et al.
Publicado: (2015)

Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study
por: Al-Sakran, Lina, et al.
Publicado: (2019)

Health service utilization in immigrants with multiple sclerosis
por: Rotstein, Dalia L., et al.
Publicado: (2020)

High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis
por: Rotstein, Dalia, et al.
Publicado: (2021)

A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada
por: McKay, Kyla, et al.
Publicado: (2017)

Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment
por: Shirani, Afsaneh, et al.
Publicado: (2015)

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
por: Kowalec, Kaarina, et al.
Publicado: (2017)

Differing trends in the incidence of vascular comorbidity in MS and the general population
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

Women's Health in Multiple Sclerosis: A Scoping Review
por: Ross, Lindsay, et al.
Publicado: (2022)

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment
por: Cohen, Jeffrey A, et al.
Publicado: (2019)

Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental health
por: Razaz, Neda, et al.
Publicado: (2015)

Evaluating the safety of β-interferons in MS: A series of nested case-control studies
por: de Jong, Hilda J.I., et al.
Publicado: (2017)

The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes
por: Tremlett, Helen, et al.
Publicado: (2021)

Differences in the burden of psychiatric comorbidity in MS vs the general population
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases
por: Liang, Geoffrey, et al.
Publicado: (2022)

High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991–2010)
por: Kingwell, Elaine, et al.
Publicado: (2015)

Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2016)

Incidence and prevalence of multiple sclerosis in Europe: a systematic review
por: Kingwell, Elaine, et al.
Publicado: (2013)

The Barancik lecture: Comorbidity in multiple sclerosis—Looking backward, looking forward
por: Marrie, Ruth Ann
Publicado: (2023)

The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry
por: Nickerson, Molly, et al.
Publicado: (2013)

Five-minute Apgar score as a marker for developmental vulnerability at 5 years of age
por: Razaz, Neda, et al.
Publicado: (2016)

Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
por: Kim, Su-Hyun, et al.
Publicado: (2019)

The effect of smoking on the symptoms and progression of multiple sclerosis: a review
por: Shirani, Afsaneh, et al.
Publicado: (2010)

Administrative data for observational research in multiple sclerosis: Opportunities and challenges
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7gfc754nqkv7po1ko715btkncm